Asia Pacific Heart Valve Device Market Will More Than Double To $815 Million By 2022

March 10, 2014

Launch of Transcatheter Technologies In Australia and China In 2014 Will Be Major Growth Driver, According to Findings from Decision Resources Group

BURLINGTON, Mass., March 10, 2014 /PRNewswire/ Decision Resources Group finds that the Asia Pacific heart valve device market will more than double through 2022 with the introduction of transcatheter heart valves. Already available in South Korea, these devices are expected to be launched in China and Australia this year and in India in 2016. Similar to what has been seen in the U.S. and Europe, the adoption of these expensive products into previously untreated patient populations will drive significant revenue growth for companies in this space. By 2022, this market will be valued at almost $815 million.


Other key findings from the Medtech 360 report entitled Asia Pacific Markets for Heart Valve Devices 2014:

    --  China and India have younger populations than South Korea or Australia.
        This will be reflected in a higher proportion of mechanical heart valve
        procedures, which are generally performed on younger patients.
    --  Demand for mechanical heart valve procedures will also be driven by high
        rates of rheumatic fever in China and India as well as among Australia's
        indigenous population. This is because rheumatic fever increases the
        risk of developing valvular disease, typically at a younger age.
    --  However, the market will continue to shift in favor of tissue heart
        valves, which are now being designed to be more durable--a previous key
        disadvantage of these products.
    --  The adoption of transcatheter heart valve procedures will be
        particularly faster in Australia, where physicians are better trained to
        perform these treatments. Despite a lack of physician training in South
        Korea, adoption will be similar, primarily driven by a general
        reluctance among older patients to undergo open heart surgery.

Comments from Decision Resources Group Analyst Leila Bautista:

    --  "A lack of training continues to be a problem in the Asia Pacific
        region. This will hinder the adoption of transcatheter heart valve
        devices--which are associated with a steep learning curve--as well as
        adoption of heart valve repairs. While there is a preference to preserve
        the native heart valve, a repair is more complex compared to a
    --  "While Medtronic and Edwards Lifesciences are both positioned to be
        leaders in the emerging Asia Pacific transcatheter heart valve device
        market, Medtronic holds a key advantage due to its strong recognition in
        the region from its broader portfolio of cardiology devices. In
        particular, Medtronic has strong on-the-ground infrastructure, including
        training centers."

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus